BioAffinity Technologies opened higher at $2.43, compared with its previous close of $2.43. In the last trading session, the stock traded between $2.29 and $2.45. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in BioAffinity Technologies is now worth
$ 0.94
Resulting in a loss of
$ 99.06 (99.06%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
$-0.09 (-3.51%)
Day High
$2.45
Day Low
$2.29
Day Open
$2.43
Prev Close
$2.43
Volume
45,808
1W Return
-21.87%
1M Return
-40.06%
3M Return
389.54%
6M Return
18.78%
1Y Return
8.33%
Fundamentals
Market Cap ($ Mn)
4
PE Ratio
-
PB Ratio
0.58
PEG Ratio
-
ROE
-412.21%
ROCE
-297.55%
EPS (TTM)
$-7.44
Investment Returns
1 Week
-21.87%
1 Month
-40.06%
3 Months
389.54%
6 Months
18.78%
9 Months
135.65%
Financials
Quarterly
All values in $ Mn
1.9
Mar 25
1.3
Jun 25
1.4
Sep 25
1.5
Dec 25
1.4
Mar 26
1.5
Jun 26
Updates
7Nov
BioAffinity Technologies reports Q3 revenue drop to $1.1M
Q3 revenue fell to $1.1 million from $1.4 million YoY. Net loss widened to $5.3 million from $5.1 million. CyPath Lung unit sales doubled year-to-date. Ordering physicians increased 89% in Q3 2026. Cash position dropped to $2.6 million from $6.4 million.
6 days ago
15Oct
bioAffinity Technologies to present CyPath Lung data at CHEST 2026
bioAffinity Technologies to present CyPath Lung clinical utility at CHEST 2026. Presentation highlights CyPath Lung's 99% negative predictive value for lung cancer. Company discusses preliminary data on investigational asthma and COPD test. Medical and Scientific Advisory Board to meet regarding federal healthcare expansion.
28 days ago
9Oct
bioAffinity Technologies closes $4 million registered direct offering
bioAffinity Technologies closed its $4 million registered direct offering on October 9, 2026. Common stock sold at $6.122 per share; pre-funded warrants at $6.115. Concurrent private placement issued warrants for 980,072 shares at $6.122 exercise price. Net proceeds will fund working capital and CyPath Lung sales growth.
